文献速递慢性肾脏病

FIDELITY分析:非奈利酮联合SGLT-2i和GLP-1RA在CKD中的应用

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD.
PubMed 文献 · Kidney Int Rep · 2025-11-28

FIDELITY汇总分析评估非奈利酮联合SGLT-2i和/或GLP-1RA在CKD合并T2D患者中的疗效与安全性。结果显示,非奈利酮在联合用药亚组中降低UACR和SBP,且eGFR下降更慢,安全性不受联合用药影响。

要点

  • 非奈利酮联合SGLT-2i和/或GLP-1RA可协同降低UACR和SBP。
  • 非奈利酮在各亚组中均延缓eGFR下降,联合用药不改变安全性。
  • 因高钾血症停药或住院的事件发生率低。

核心结论

  • 非奈利酮联合SGLT-2i和/或GLP-1RA在CKD合并T2D患者中显示出协同肾脏保护和降压作用。

研究设计与样本

  • FIDELITY是两项临床试验的汇总个体水平分析,本亚分析按基线联合用药分为四组:联合SGLT-2i和GLP-1RA组(n=167)、无SGLT-2i或GLP-1RA组(n=11,341)、仅SGLT-2i组(n=706)、仅GLP-1RA组(n=776)。

主要发现

  • 从基线至第4个月,非奈利酮在所有联合用药亚组中降低UACR和SBP的幅度均大于安慰剂。
  • 第12个月时,联合SGLT-2i和GLP-1RA的非奈利酮亚组UACR降低差异最大。
  • 所有亚组中,非奈利酮组eGFR下降较安慰剂组更慢。
  • 非奈利酮的安全性特征未因联合SGLT-2i和/或GLP-1RA而改变,因高钾血症导致停药或住院的事件发生率低。

临床怎么用

  • 在CKD合并T2D患者中,非奈利酮可与SGLT-2i和/或GLP-1RA联合使用,以增强肾脏保护和降压效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of 2 clinical trials. Considering that treatment recommendations increasingly support combination therapies for CKD and T2D, this FIDELITY subanalysis assessed the efficacy and safety of finerenone versus placebo when taken with concomitant sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and/or glucagon-like peptide-1 receptor agonist (GLP-1RA). METHODS: Change in urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR) and systolic blood pressure (SBP) over time, and treatment-emergent adverse events (TEAEs) were analyzed in subgroups by concomitant medication at baseline as follows: (i) combined SGLT-2i and GLP-1RA (n = 167), (ii) no SGLT-2i or GLP-1RA (n = 11,341), (iii) SGLT-2i only (n = 706), and (iv) GLP-1RA only (n = 776). RESULTS: Finerenone led to a greater reduction than with placebo in UACR and SBP from baseline to month 4 across all concomitant medication subgroups. At month 12, the greatest UACR reduction difference between the treatment arms was observed in the finerenone subgroup with combined SGLT-2i and GLP-1RA. Decline of eGFR from baseline was slower with finerenone than with placebo across all subgroups. The safety profile of finerenone was not modified by concomitant SGLT-2i and/or GLP-1RA use; hyperkalemia events leading to treatment discontinuation or hospitalization with finerenone were low. CONCLUSION: The concomitant use of finerenone with SGLT-2i and/or GLP-1RA demonstrated potential synergistic effects on preserving kidney function and reducing blood pressure versus placebo in people with CKD and T2D.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Singh AK, Anker SD, Pitt B, et al. A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD. Kidney Int Rep. 2025. PMID: 41630895. doi:10.1016/j.ekir.2025.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。